

BioCLIA Autoimmune Control Set, MPO

Cat.No.	Kit Size
MY00315	2 X 1 mL
MY00366	4 X 1 mL

INTENDED USE

The BioCLIA Autoimmune Control Set, MPO is intended for the quality control purposes of the BioCLIA MPO performed on the BioCLIA 6500 and BioCLIA 500. For professional *in vitro* diagnostic use only.

SUMMARY AND EXPLANATION

Serological detection of anti-neutrophil cytoplasmic antibodies (ANCAs) contributes to the autoimmune diseases diagnosis include Wegener's granulomatosis, acute progressive glomerulonephritis, polyarteritis, ulcerative colitis, and primary sclerosing cholangitis. ^{1, 2} PR3, MPO and GBM are general indicators for the detection of ANCAs, which can greatly improve the early diagnostic rate of renal vasculitis. Peroxidase, also called myeloperoxidase (MPO), is an important iron contained lysosome, exists in the aniline blue particles of myeloid cells (mainly neutrophils and monocytes). MPO is an indicator for the myeloid cells, the activity of neutrophils, or function of eosinophilic polymorphonuclear leukocyte (PMN). In addition, MPO is considered to be the target antigen of most pANCA. pANCA may occur in diseases other than vasculitis. ^{3, 4, 5}

MPO is closely related to the occurrence and development of human diseases such as the microscopic arterial inflammation (MPA), necrotizing crescents glomerulonephritis (NCGN), variational granulomatous vasculitis (CSS), *etc.* The antibody titer concerns disease activity and can be used for early diagnosis, treatment, recurrence and guidance of treatment. The highly expression of MPO antibody indicates the occurrence of necrotizing vasculitis or idiopathic NCGN, which can reach 99% specificity for the diagnosis of Panca. ^{6, 7, 8, 9}

MATERIALS SUPPLIED

• **MPO Control N** Barcode labeled tubes with buffer containing human antibodies to MPO in stabilizers and preservatives. Ready to use, 1 mL.



Preservatives: 0.0015% < Proclin 300 < 0.6%.

• **MPO Control P** Barcode labeled tubes with buffer containing human antibodies to MPO in stabilizers and preservatives. Ready to use, 1 mL.

Control	Ρ	
---------	---	--

Preservatives: 0.0015% < Proclin 300 < 0.6%.

The Control Code contains controls' information is provided in each kit.

Target value and acceptance range for the controls are indicated on the card provided in each kit.

WARNINGS AND PRECAUTIONS

- For professional in vitro diagnostic use only.
- Do not use any controls beyond their expiration dates.
- Do not mix controls from different lots unless specified.
- Instructions must be carefully followed for using and storing of controls. Any modification in procedure may interfere with the results.
- Controls and contaminated vials must be handled strictly following safety guidelines or rules of biological hazards to ensure the users' and environmental safety.
- Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established!

Precautions:

W Human serum is added in the controls.

 The human derived material in this product was tested by FDA approved methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), Anti-HCV and HIV 1/2 antibodies. Handle as if potentially infectious. 7 Avoid contacting with skin and eyes. Do not empty into drains. Wear suitable protective clothing.

- Proclin 300 is added in the controls at concentration between 0.0015% - 0.6%.
- Controls contain chemical and biological components. Avoid ingesting or splashing onto skin and mucous membrane. If direct contact with controls happens, rinse the contact surface with plenty of water immediately and see a doctor if necessary.

STORAGE CONDITIONS

- Store the kit at 2-8 °C.
- The shelf life of the unopened kit is 12 months from day of production.
- Vial opened controls could be used for 28 successive days, exposure no more than 2 hours each time when kept uncapped and is good for up to 35 controls, after which the reagent must be discarded.
- Avoid repeated freezing and thawing.

ASSAY PROCEDURE

Detailed information about operating the BioCLIA instruments can be taken from the Instrument User's Manual.



Note that, it is important to perform all routine maintenance procedures for optimal performance.

Control

The control procedure should be done before running the specimens each day. Users also can adjust the control procedure period according to their own lab frequency.

Each Laboratory should establish its own reference ranges.

Programming and Running samples

- Put the kit into the corresponding position of the reagent chamber of the fully automatic chemiluminescence analyzer. The information of the kit can be uploaded into the instrument system through the scanning of reagent barcode, and can also be set through the supporting software of the instrument.
- The information of calibrator / quality control is identified by scanning the calibrator / control barcodes, and the position of calibrator / quality control is assigned in the instrument system.
- 3. The sample to be tested is placed on the instrument sample rack chamber, and the corresponding test information is edited through the instrument supporting software.
- 4. Start the operation procedure, and all calibrator / quality control / sample processing steps will be automatically executed.

TRACEABILITY

The reported values were determined over multiple runs on the BioCLIA 6500 and BioCLIA 500 using specific lots of reagents against an in-house standard. DGP IgA results are reported in RU/mL which is interpreted from relative light unit (RLU). Method comparison test showed good sensitivity and specificity of tested assay.

LIMITATIONS

- The controls are designed for control of the same lot of BioCLIA Autoimmune Reagent Kit.
- The controls can be kept uncapped onboard the instrument up to 2 hours for each time of usage. And a total up to 35 controls are suggested, for any longer period of time, the reagent should be discarded, otherwise may result in improper results.

SYMBOLS

REF	Catalog Number	\Box	Use-by date
IVD	In Vitro diagnostic medical device	LOT	Lot Number
+2°C	Store between +2°C and +8°C	Ĩ	Consult Instruction for Use
	Manufacturer	EC REP	Authorized Representative in the European Community
CE	CE Marking	¥	Contains Sufficient for <n>Tests</n>
S	Biological Risk	$\langle \mathbf{i} \rangle$	GHS07 Warning
Control N	Negative Control		
Control P	Positive Control		

REFERENCE

 Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney International 2000;57:846-62.

2. Bossuyt X. Serologic markers in inflammatory bowel disease. Clinical Chemistry 2006;52:171-81.

3. Blairjohnson M, Fiedler T, Fenna R. Human myeloperoxidase: structure of a cyanide complex and its interaction with bromide and thiocyanate substrates at 1.9 A resolution. Biochemistry 2001;40:13990-7.

4. Klebanoff SJ. Myeloperoxidase: friend and foe. Journal of Leukocyte Biology 2005;77:598-625.

5. Jr KJ, Pember SO, Barnes KC, Shapira R, Spitznagel JK, Martin LE. Differential distribution of distinct forms of myeloperoxidase in different azurophilic granule subpopulations from human neutrophils. Biochemical & Biophysical Research Communications 1983;114:296-303.

6. Zhang R, Brennan M-L, Fu X, Aviles RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama 2001;286:2136-42.

7. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arteriosclerosis, thrombosis, and vascular biology 2005;25:1102-11.

8. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacology & therapeutics 2006;111:16-26.

9. Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. Nature Reviews Rheumatology 2014;10:494-501.

10. Richmond JY, Mckinney RW. Biosafety in microbiological and biomedical laboratories: U.S.GPO. 1999.



HOB Biotech Group Corp., Ltd. C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123, China

CONTACT INFORMATION:

TEL (+86)512-69561996

Fax (+86)512-62956652 WEBSITE: www.hob-biotech.com

CUSTOMER SERVICE: HOB Biotech Group Co., Ltd CUSTOMER SERVICE: TEL (+86)4008601202

EC REP

EUROPE REPRESENTATIVE: Emergo Europe **ADDRESS/LOCATION:** Prinsessegracht 20, 2514 AP The Hague, The Netherlands



The eIFU is available on Website:

http://en.hob-biotech.com/usercenter/login.aspx

TECHNICAL ASSISTANCE

For technical assistance, contact your National Distributor.

Date of issue: 17th March 2019 Date of revision: 20th December 2021 Change Control Number: CN21129E Version: A/1 (EN)